PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Plenary Keynotes Announced for Biomarker Summit 2012 - March 15-16 in San Diego, California - GTC is pleased to announce three Keynote speakers at the Biomarker Summit 2012, March 15-16 in San Diego, CA. Drs. Carolyn Compton, Steven J. Skates and Khusru Asadullah will present during the Summit plenary session - GTCbio.com
Plenary Keynotes Announced for Biomarker Summit 2012 - March 15-16 in San Diego, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2012/02/15 - GTC is pleased to announce three Keynote speakers at the Biomarker Summit 2012, March 15-16 in San Diego, CA. Drs. Carolyn Compton, Steven J. Skates and Khusru Asadullah will present during the Summit plenary session - GTCbio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Prof. Dr. med. Khusru Asadullah, Vice President, Head of Global Biomarker, Bayer Pharma HealthCare will provide the keynote presentation,“Grants for Targets and Biomarkers - a Novel Open Innovation Initiative in Drug Discovery”.

Dr . Compton, President & CEO, Critical Path Institute, will provide a regulatory update and how it concerns the pharmaceutical industry. Prior to joining Critical Path Institute, Dr. Compton was the Director of the Office of Biorepositories and Biospecimen Research (OBBR) and the Executive Director of the Cancer Human Biobank (caHUB) project at the National Cancer Institute.

Dr. Skates, Associate Professor of Medicine, Massachusetts General Hospital Cancer Center will present on biomarker research from an academic perspective. Dr. Skates attended the University of Western Australia.

About the Biomarker Summit 2012
Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in diagnostics, oncology and the business of biomarkers. This truly one-of-a-kind, single-stop event has been carefully developed to provide insights into critical issues, discoveries, developments and investments from the most respected names within the biomarker industry. The Summit includes the following tracks:

• 6th Biomarker Development Conference
• 4th Oncology Biomarker Conference
• Biomarkers & Diagnostic Conference
• Biomarkers Partnering & Deal-Making Conference
• GTC develops independent events bringing together executive level professionals to acquire the latest industry data while networking and building important business relationships. You may visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Plenary Keynotes Announced for Biomarker Summit 2012 - March 15-16 in San Diego, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  SKS Media | SKS Associates Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)